Related Experiment Videos
Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Pietro Annovazzi1, Antonio Bertolotto2, Vincenzo Brescia Morra3
1Multiple Sclerosis Study Center, ASST Valle Olona, Gallarate, VA, Italy. pietro.annovazzi@asst-valleolona.it.
Neurology and Therapy
|November 12, 2018
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Epigenetic Insights in Pediatric Multiple Sclerosis: DNA Methylation Highlights an Involvement of Epstein-Barr Virus Infection and Host Immune Networks.
Neurology(R) neuroimmunology & neuroinflammation·2026
Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.
The journal of headache and pain·2026
Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience.
Multiple sclerosis journal - experimental, translational and clinical·2026
Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation.
Multiple sclerosis (Houndmills, Basingstoke, England)·2026
ATM-kinase deficiency triggers early multi-compartment remodeling of the cerebellar microenvironment.
Acta neuropathologica communications·2026
Impact of Oral Cladribine on TSPO-PET-Measurable Immune Cell Activation in Multiple Sclerosis.
Neurology and therapy·2026
Synergistic lipase inhibition by Garcinia parvifolia metabolites: a 1H NMR-based metabolomic deciphering of ligand interactions.
Metabolomics : Official journal of the Metabolomic Society·2026
Design, synthesis, and evaluation of fluorescent probes targeting DNA polymerase theta (Polθ) for inhibitor screening and cellular imaging.
European journal of medicinal chemistry·2026
Proteolysis Targeting Chimera (PROTAC) Linkerology Enhances the CDK-Degradation Selectivity Profile of a Multi-CDK Inhibitor: Discovery of Potent, Anti-Leukemic CDK9 Degraders.
ACS pharmacology & translational science·2026